Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Third-party royalties & milestone payments included in by Year
Third-party royalties & milestone payments included in cost of sales ($M) ($M)
Moderna Third-party royalties & milestone payments included in: $88M in FY2025, down 43.2% from a year earlier.
Latest, FY2025
88
Period ended Dec 31, 2025
Change on a year earlier
-43.2%
155 in FY2024
History
5 years
Since FY2021
Sources
2
Documents cited below
Where the FY2025 figure comes from
“For the years ended December 31, 2025, 2024, and 2023 we recognized $ 88 million, $ 155 million, and $ 301 million, respectively, of royalties and commercial milestone payments associated with our net product sales, which was recorded to cost of sales in our consolidated statements of operations.”
Source: FY2025 10-K ↗
Reported in Form 10-Q / 10-K MD&A & Form 8-K Earnings Releases.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Third-party royalties & milestone payments included in cost of sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 88 | -43.2% | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 155 | -48.5% | FY2025 10-K ↗ |
| FY2023 | Dec 31, 2023 | 301 | -72.6% | FY2025 10-K ↗ |
| FY2022 | Dec 31, 2022 | 1,100 | +71.6% | FY2023 10-K ↗ |
| FY2021 | Dec 31, 2021 | 641 | – | FY2023 10-K ↗ |
Cite this data
StockData. (2026). Moderna Third-party royalties & milestone payments included in ($M), annual FY2021–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-royalties
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.